Samsung Biologics Nears $2 Billion PolyPeptide Takeover

Samsung Biologics is on the cusp of a $2 billion acquisition of PolyPeptide Group, as initial results from the proposed tender offer indicate strong shareholder support. During the offer period from September 15 to October 12, 29,014,418 shares were tendered, representing an impressive 87.88% of the shares targeted for acquisition.

This exceeded the minimum acceptance threshold of 66.7% by a significant margin, with 18,375,000 shares of PolyPeptide's largest shareholder, Draupnir Holding, also participating in the tender. The acquisition is valued at 1.46 billion Swiss francs, or approximately 2.7 trillion won, making it the largest M&A transaction in South Korea's pharmaceutical and biotechnology industry, surpassing a 2022 deal worth approximately 2.3 trillion won.

This strategic move aligns with Samsung Biologics' goal to capitalize on the rapidly growing peptide therapeutics market, as these short chains of amino acids offer high biocompatibility and target specificity, finding applications in treatments for obesity and diabetes. The global obesity treatment market is projected to reach 200 trillion won by 2035.

Samsung Biologics aims to expand its contract development and manufacturing organization (CDMO) portfolio beyond antibody therapeutics, mRNA, and antibody-drug conjugates (ADCs) into peptide-based medicines. The next stage of the transaction includes an additional tender period from October 19 to October 30, followed by regulatory approvals in several jurisdictions.

Once completed, the company expects to settle the deal within 10 business days, with completion targeted for late November. Samsung Biologics plans to leverage its expertise in manufacturing alongside PolyPeptide's technological capabilities to maximize synergies and address the expanding market demand for peptide-based medicines.

This expansion is expected to bolster Samsung Biologics' growth prospects and provide new sources of medium- to long-term growth. Despite the anticipated acquisition, analysts caution that a scheduled three-week labor union strike, beginning October 26, coupled with a previous strike in May that disrupted approximately 150 billion won in revenue, could pose a near-term challenge.

Addressing supply chain reliability will be crucial for Samsung Biologics as it navigates the complexities of the CDMO industry.